Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Overview on how oncogenic Kras promotes pancreatic carcinogenesis by inducing low intracellular ROS levels

1 Jan 2013

Abstract excerpt

Pancreatic ductal adenocarcinoma (PDAC) is a devastating disease without clearly known disease causes. Recent epidemiological and animal studies suggest that the supplementation of dietary antioxidants (e.g., vitamins C and E) decreases cancer risk, implying that increased reactive oxygen species (ROS) may play a role in pancreatic carcinogenesis. However, oncogenic Kras mutations (e.g., Kras(G12D)), which are...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer, Hypoxia, and Metabolism
Share to Genomics, phytochemicals, and oxidative stress
Share to Pancreatic and Hepatic Oncology Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 24062691
DOI: 10.3389/fphys.2013.00246

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Overview on how oncogenic Kras promotes pancreatic carcinogenesis by inducing low intracellular ROS levelsPMID 24062691Read ↗

Targeting reactive oxygen species in development and progression of pancreatic cancer.Semantic proximity Read ↗

KRAS G12D mutation eliminates reactive oxygen species through the Nrf2/CSE/H 2S axis and contributes to pancreatic cancer growth.Semantic proximity Read ↗

Undermining Glutaminolysis Bolsters Chemotherapy While NRF2 Promotes Chemoresistance in KRAS-Driven Pancreatic Cancers.Semantic proximity Read ↗

KRas, ROS and the initiation of pancreatic cancer.Semantic proximity Read ↗

NADK is activated by oncogenic signaling to sustain pancreatic ductal adenocarcinomaSemantic proximity Read ↗

Ferroptosis: New Strategies and Ideas for the Treatment of Pancreatic Ductal Adenocarcinoma.Semantic proximity Read ↗

Vertical RAS-pathway inhibition in pancreatic cancer drives therapeutically exploitable mitochondrial alterationsSemantic proximity Read ↗

The impact of oncogenic RAS on redox balance and implications for cancer development.Semantic proximity Read ↗

Nrf2 Activation Sensitizes K-Ras Mutant Pancreatic Cancer Cells to Glutaminase Inhibition.Semantic proximity Read ↗

Nrf2 promotes mutant K-ras/p53-driven pancreatic carcinogenesis.Semantic proximity Read ↗

ROS in cancer therapy: the bright side of the moon.Semantic proximity Read ↗

Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.